GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Biomerica Inc (NAS:BMRA) » Definitions » Earnings Power Value (EPV)

Biomerica (Biomerica) Earnings Power Value (EPV) : $-4.41 (As of Feb24)


View and export this data going back to 1978. Start your Free Trial

What is Biomerica Earnings Power Value (EPV)?

As of Feb24, Biomerica's earnings power value is $-4.41. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Biomerica Earnings Power Value (EPV) Historical Data

The historical data trend for Biomerica's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomerica Earnings Power Value (EPV) Chart

Biomerica Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.88 -0.93 -2.24 -3.47 -3.56

Biomerica Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.52 -3.56 -3.74 -3.96 -4.41

Competitive Comparison of Biomerica's Earnings Power Value (EPV)

For the Medical Devices subindustry, Biomerica's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomerica's Earnings Power Value (EPV) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Biomerica's Earnings Power Value (EPV) falls into.



Biomerica Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Biomerica's "Earning Power" Calculation:

Average of Last 20 Quarters Last Quarter
Revenue 8.71
DDA 0.41
Operating Margin % -93.31
SGA * 25% 1.24
Tax Rate % -0.60
Maintenance Capex 0.15
Cash and Cash Equivalents 5.32
Short-Term Debt 0.32
Long-Term Debt 0.54
Shares Outstanding (Diluted) 16.82

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = -93.31%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = $8.71 Mil, Average Operating Margin = -93.31%, Average Adjusted SGA = 1.24,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 8.71 * -93.31% +1.24 = $-6.892608215 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = -0.60%, and "Normalized" EBIT = $-6.892608215 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = -6.892608215 * ( 1 - -0.60% ) = $-6.9340672534132 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 0.41 * 0.5 * -0.60% = $-0.0012228495 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = -6.9340672534132 + -0.0012228495 = $-6.9352901029132 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Biomerica's Average Maintenance CAPEX = $0.15 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Biomerica's current cash and cash equivalent = $5.32 Mil.
Biomerica's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 0.54 + 0.32 = $0.862 Mil.
Biomerica's current Shares Outstanding (Diluted Average) = 16.82 Mil.

Biomerica's Earnings Power Value (EPV) for Feb24 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( -6.9352901029132 - 0.15)/ 9%+5.32-0.862 )/16.82
=-4.41

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( -4.4141006505457-0.6653 )/-4.4141006505457
= N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.


Biomerica  (NAS:BMRA) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Biomerica Earnings Power Value (EPV) Related Terms

Thank you for viewing the detailed overview of Biomerica's Earnings Power Value (EPV) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomerica (Biomerica) Business Description

Traded in Other Exchanges
N/A
Address
17571 Von Karman Avenue, Irvine, CA, USA, 92614
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Europe market.
Executives
John P. Kenny director 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Zacharys Irani director, officer: Cheif Executive Officer 17571 VON KARMAN AVE., IRVINE CA 92614
Gary Lu officer: Chief Financial Officer 12136 AHERN CT, TUSTIN CA 92782
Allen Barbieri director
Catherine Coste director 966 OCHO RIOS DR, DANVILLE CA 94526
David Moatazedi director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Steven Sloan officer: Chief Financial Officer 114 TERRAPIN, IRVINE CA 92618
Mark A Sirgo director C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Francis E Capitanio officer: President-diagnostics 1533 MONROVIA AVENUE, NEWPORT BEACH CA 92663
Janet Moore director, 10 percent owner, officer: Secretary 1533 MUNROVIA AVE, NEWPORT BEACH CA 92663
Jane Emerson director 1533 MONROVIA AVE, NEWPORT BEACH CA 92663
William Snider other: Greater than 5% holder 4800 MONTGOMERY LANE, SUITE 230, BETHESDA MD 20814
Broadoak Fund The other: Greater than 5% holder 7201 WISCONSIN AVE. #630, BETHESDA MD 20814
John Roehm director 1533 MONROVIA AVE., NEWPORT BEACH CA 92663